A chemist by training who has decades of leadership experience in business development and business strategy, with a long-standing focus on oncology.
Jeb Keiper is the Chief Executive Officer of Nimbus Therapeutics, a biotechnology company coupling targets selected based on causal human biology with structure-based drug discovery and development. Mr. Keiper has served as President and Chief Executive Officer and as a member of the Nimbus board of directors since October 2018. He previously served as Chief Business Officer from November 2014 to October 2018 and as Chief Financial Officer from February 2017 to October 2018. Since joining Nimbus, Mr. Keiper has overseen the discovery and development of three programs into clinical testing across a range of indications, raised over $400M in equity funding, executed deals worth over $7B, and returned over $4B in gains back to equity holders.
Prior to joining Nimbus, Mr. Keiper served as the Vice President of Business Development at GSK Oncology (a subsidiary of GlaxoSmithKline plc (NYSE: GSK)) from March 2011 to October 2014, where he was responsible for identifying and concluding several critical collaborations for GSK in Oncology, including the Novartis-GSK Oncology integration, and spent a decade at GSK in various business development leadership roles. Prior to GSK, Mr. Keiper was a consultant at McKinsey & Company starting in September 2000-2002 then September 2004 to 2005, after having started his career as a pharmaceutical chemist at Pfizer Inc. (NYSE: PFE) in 1998.
Mr. Keiper currently serves as a member of the board of directors at private biotechnology companies Cardurion Pharmaceuticals, Inc., and ROME Therapeutics, Inc.
Mr. Keiper received two B.S. degrees, one in chemistry and one in chemical engineering, as well as an M.S. in chemical engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management with joint program in biomedical enterprises with the Harvard Medical School.